It not only could effectively distinguish AD from controls [area under the curve (AUC) > 0.97], and further distinguished preclinical (AUC > 0.89) and MCI (AUC > 0.85) from controls, but the higher levels of plasma GFAP, the more accurate predictive value for risk of AD progression [8]. The gene discussed is GFAP; the disease is Alzheimer disease.